Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document is very short (320 characters) and contains a table listing dates, analyst/investor names, and types of meetings (videoconferences). There is no financial data, no report content, no regulatory references, or any indication of a formal report or announcement. The content resembles a schedule or record of investor meetings rather than a formal filing. Given the lack of substantive financial or regulatory content, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2020-12-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 90% confidence The document text is extremely short (122 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report title, no regulatory references, and no indication of the document's purpose. Given the lack of content, it cannot be classified as a full report or detailed filing. According to the rules, such minimal content with no report text defaults to Regulatory Filings (RNS) as a fallback category.
2020-12-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 60% confidence The document is very short (380 characters) and contains a simple table listing dates, fund/investor names, and types of meetings (videoconference one-on-one). There is no financial data, no report content, no regulatory references, or any indication of a formal filing. The content resembles a schedule or summary of investor meetings rather than a formal report or announcement. Given the lack of substantive financial or regulatory information, and the nature of the content, the best fitting category is Investor Presentation (IP), as it relates to investor communications and presentations, albeit in a minimal form. Confidence is moderate due to limited content but the context aligns best with IP rather than other categories.
2020-12-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice from Gland Pharma Limited addressed to the National Stock Exchange of India. It announces the schedule of upcoming analyst and institutional investor meetings, specifically a video conference on November 26, 2020. The document references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain any financial data, results, or detailed presentations. It is an announcement of meetings rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-11-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing about the schedule of analyst and institutional investor meetings. It references regulatory compliance (Regulation 30 of SEBI Listing Obligations) and provides dates and types of meetings. There is no financial data, no detailed report, no voting results, no management changes, and no audit information. The document is an announcement related to investor relations but does not contain a full investor presentation or financial report. Given the short length (1567 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.